Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

• Main Authors: David A. Reardon, James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, Scott Turner, Sith Sathornsumetee, Jeremy N. Rich, Susan Boulton, Eric S. Lipp, Henry S. Friedman, James J. Vredenburgh
• 其他作者: Dana-Farber Cancer Institute
• 格式: Article
• 出版: 2018
• 主題: Biochemistry, Genetics and Molecular Biology; Medicine; Neuroscience
• 在線閱讀: https://repository.li.mahidol.ac.th/handle/123456789/13791

Although outcome following bevacizumab among recurrent grade IV malignant glioma patients is documented as poor by several analyses, outcome for recurrent grade III patients following bevacizumab therapy has not been specifically evaluated. We performed a pooled analysis of 96 recurrent grade III ma...